GGrantIndex
← Leaderboards

Jennifer McCormack

The Emmes Company, Llc

Google Scholar ↗PubMed ↗ORCID ↗
$25,403,412
Attributed
$25,403,412
Total exposure
2
Grants
2
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $10.3M · FY2022–25
$20M$15M$10M$5M$0
'22
'23
'24
'25

Funding mix

By agency

NIH$25,403,412 · 2

By mechanism

N01$25,403,412 · 2

Top collaborators

No co-investigators on record.

Most similar at The Emmes Company, Llc

Same institution · by research overlap

Others in their field

Other Rising Stars on “Public Health”

Research focus

Public HealthUnited States National Institutes Of HealthOpioid MisuseHelping To End Addiction Long-TermOpioidSpeedOpiate AddictionContractsOpioid EpidemicStatisticsBuprenorphineSupport ContractsSubstance MisuseOpioid Use DisorderNational Institute Of Drug AbuseClinical TrialsValidationMethamphetamine Use DisorderKetaminePharmaceutical PreparationsAccident And Emergency DepartmentDrug AddictionDoseData Analyses

Grant awards (26)

DATA AND STATISTICAL ANALYSIS FOR GLP-1 AS AN ADJUNCT TO BUPRENORPHINE. MAY 21, 2025 - FEBRUARY 29, 2028. N01DA-22-2253. TASK ORDER NO. 75N95025F00002 (TO26).$1,397,875
N01 · FY2025 · DA · contact PI
KETAMINE FOR METHAMPHETAMINE USE DISORDER STUDY (CTN-0132). 09/28/2022 - 08/21/2025. DSC6. 75N95022F00004 (TO4).$500,799
N01 · FY2025 · DA · contact PI
OPTIMIZING RETENTION, DURATION AND DISCONTINUATION STRATEGIES FOR OPIOID USE DISORDER PHARMACOTHERAPY (CTN-0100). AUGUST 15, 2024 TO MARCH 31, 2028. N01DA-22-2253. TASK ORDER NO. 75N95024F00007 (TO23)$1,510,879
N01 · FY2024 · DA · contact PI
HEAL MANAGEMENT AND SUPPORT. AUGUST 2, 2024 TO AUGUST 1, 2025. N01DA-22-2253. TASK ORDER NO. 75N95024F00005 (TO21).$1,284,879
N01 · FY2024 · DA · contact PI
RURAL EXPANSION OF MEDICATION TREATMENT FOR OPIOID USE DISORDER (CTN-0102). AUGUST 1, 2024 TO MARCH 31, 2026. N01DA-22-2253. TASK ORDER NO. 75N95024F00008 (TO24).$771,451
N01 · FY2024 · DA · contact PI
EXEMPLAR HOSPITAL INITIATION TRIAL TO ENHANCE TREATMENT ENGAGEMENT (CTN-0098). JUNE 10, 2024 TO NOVEMBER 1, 2026. N01DA-22-2253. TASK ORDER NO. 75N95024F00003 (TO19).$622,266
N01 · FY2024 · DA · contact PI
EMERGENCY DEPARTMENT-INITIATED BUPRENORPHINE AND VALIDATION NETWORK TRIAL (CTN-0099). 08/15/2023 - 10/18/2024. N01DA-22-2253. TASK ORDER 75N95023F00007 (TO11).$147,495
N01 · FY2024 · DA · contact PI
SUBTHRESHOLD OPIOID USE DISORDER PREVENTION TRIAL (CTN-0101). AUGUST 1, 2024 TO MARCH 31, 2026. N01DA-22-2253. TASK ORDER NO. 75N95024F00004 (TO20).$113,621
N01 · FY2024 · DA · contact PI
NIDA DATA, STATISTICS, AND CLINICAL TRIAL SUPPORT CENTER MANAGEMENT AND SUPPORT. 03/01/2023 - 02/29/2024. N01DA-22-2253. TASK ORDER 75N95023F00003 (TO7).$2,192,292
N01 · FY2023 · DA · contact PI
DSC MANAGEMENT AND SUPPORT FOR HELPING TO END ADDICTION LONG-TERM INITIATIVE (HEAL). 08/02/2023 - 08/01/2024. N01DA-22-2253. TASK ORDER 75N95023F00009 (TO13).$2,112,800
N01 · FY2023 · DA · contact PI
STANDARD AND HIGH DOSE ED BUPRENORPHINE INDUCTION. 09/15/2023 - 05/31/2026. N01DA-22-2253. TASK ORDER 75N95023F00005 (TO9).$1,249,376
N01 · FY2023 · DA · contact PI
BETTER TOGETHER: INTEGRATING MOUD IN AFRICAN AMERICAN COMMUNITY SETTINGS. SEPTEMBER 15, 2023 TO JANUARY 31, 2026. N01DA-22-2253. TASK ORDER 75N95023F00004 (TO8).$999,995
N01 · FY2023 · DA · contact PI
CRAFT. SEPTEMBER 15, 2023 - MARCH 31, 2025. N01DA-22-2253. TASK ORDER NO. 75N95023F00011 (TO15).$799,919
N01 · FY2023 · DA · contact PI
SECONDARY ANALYSIS. SEPTEMBER 15, 2023 - SEPTEMBER 14, 2026. N01DA-22-2253. TASK ORDER NO. 75N95023F00012 (TO16)$754,669
N01 · FY2023 · DA · contact PI
MOMS STUDY IMPLEMENTATION (CTN-0080). DSC6. 08/15/2023 - 04/30/2026. N01DA-22-2253. TASK ORDER 75N95023F00006 (TO10).$500,879
N01 · FY2023 · DA · contact PI
CULTURALLY CENTERED MED. ASSISTED TREATMENT OUD IMPLEMENTATION FOR PRIMARY CARE AND ADDICTION TREATMENT PROGRAMS SERVING AI/AN (CTN-0096). 03/01/2022 - 11/01/2024. DSC6. 75N95023F00001 (TO5).$499,837
N01 · FY2023 · DA · contact PI
RTMS FOR STIMULANT USE DISORDERS (STIMULUS)(CTN-0108). 04/01/2023 - 09/01/2024. N01DA-22-2253. TASK ORDER 75N95023F00002 (TO6).$369,589
N01 · FY2023 · DA · contact PI
EMERGENCY DEPARTMENT-INITIATED BUPRENORPHINE AND VALIDATION NETWORK TRIAL (CTN-0099). 08/15/2023 - 10/18/2024. N01DA-22-2253. TASK ORDER 75N95023F00007 (TO11).$299,409
N01 · FY2023 · DA · contact PI
PEER RECOVERY SUPPORT: A BRIDGE TO TREATMENT FOR OVERDOSE SURVIVORS (CTN-0107). 08/15/2023 - 09/14/2024. N01DA-22-2253. TASK ORDER 75N95023F00008 (TO12).$263,405
N01 · FY2023 · DA · contact PI
POST-ANESTHESIA. SEPTEMBER 15, 2023 - SEPTEMBER 14, 2028. N01DA-22-2253. TASK ORDER 75N95023F00010 (TO14).$214,264
N01 · FY2023 · DA · contact PI
NIDA DATA, STATISTICS, AND CLINICAL TRIAL SUPPORT CENTER MANAGEMENT AND SUPPORT. 09/05/2022 - 09/04/2023. N01DA-22-2253. TASK ORDER 75N95022F00001 (TO$2,340,050
N01 · FY2022 · DA · contact PI
INTEGRATED CARE AND TREATMENT FOR SEVERE INFECTIOUS DISEASES AND SUBSTANCE USE DISORDERS (SUD) AMONG HOSPITALIZED PATIENTS (CTN-0121). 09/28/2022 - 02$1,399,997
N01 · FY2022 · DA · contact PI
KETAMINE FOR METHAMPHETAMINE USE DISORDER STUDY (CTN-0132). 09/28/2022 - 08/21/2025. DSC6. 75N95022F00004 (TO4).$1,399,972
N01 · FY2022 · DA · contact PI
NIDA DATA, STATISTICS, AND CLINICAL TRIAL SUPPORT CENTER MANAGEMENT AND SUPPORT. 03/01/2022 - 02/28/2023. N01DA-19-2250. TASK ORDER 75N95022F00001 (TO$1,380,980
N01 · FY2022 · DA · contact PI
MANAGEMENT OF UNHEALTHY OPIOID AND POLYSUBSTANCE USE AMONG PATIENTS IN PRIMARY CARE SETTING. 09/01/2022 - 08/14/2027. N01DA-19-2250. TASK ORDER 75N950$1,249,861
N01 · FY2022 · DA · contact PI
OFFICE-BASED METHADONE VS BUPRENORPHINE TO ADDRESS RETENTION IN MEDICATION FOR OPIOID USE DISORDER (MOUD)-A PRAGMATIC HYBRID EFFECTIVENESS/IMPLEMENTAT$1,026,853
N01 · FY2022 · DA · contact PI